Good MorningEquity markets tried to build on the previous week's strength, but the gains were fleeting. The S&P 500 closed with a small daily gain but aligned with recent highs. The move suggests a lack of momentum and increasing resistance to higher prices that may cap gains for the remainder of the summer. The CPI report was good but aligned with the outlook for FOMC rate cuts that are already priced into the market. There is a high risk that it will be a sell-the-news event, and a stock market price correction will soon follow.
The S&P 500 may not fall far. The outlook for earnings growth remains robust, and with interest rates set to drop, strength will bleed into a broader array of sectors. In this scenario, a market correction is a buy-the-dip opportunity leading to another multi-quarter rally for the index. Featured: They're not buying gold. They're buying this. (Ad) 
|
Consumer Discretionary | |
Solid-state battery technology company QuantumScape Co. (NYSE: QS) stock awakened, jumping nearly 46% on news of a new agreement with PowerCo, a subsidiary of Volkswagen AG (OTCMKTS: VWAGY). QuantumScape received much hype and fanfare in 2021 regarding its solid-state lithium-metal battery techn... Read the Full Story |
|
From Our Partners | | For 20 years, Chief Income Strategist Tim Plaehn refused to own anything that didn't pay income, including gold.
Then he found an exception: a $15 investment tied to gold that pays out every Friday. He calls it Friday Golden Payments. | | See how Tim Plaehn's Friday Golden Payments strategy works now |
|
Technology | |
NVIDIA Corp. (NASDAQ: NVDA) continues to be one of the best-performing stocks in 2024. At a split-adjusted price of $129.71, NVDA stock is up 160% in 2024. However, NVIDIA’s coattails appear to be fairly short. The market growth is limited to a relatively narrow range of stocks, mostly in la... Read the Full Story |
|
Consumer Discretionary | |
Ford Motor Company (NYSE: F) is navigating a significant transformation as the automotive sector transitions from gas power and embraces the electric vehicle (EV) future. This shift has led many investors and Ford Motor’s analyst community to wonder if now is the time to buy Ford Motor sto... Read the Full Story |
|
From Our Partners | | The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.'
He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year. | | Watch the video now to get the ticker name and full trade details |
|
Industrials | |
The iShares Russell 2000 ETF (NYSE: IWM) experienced a significant breakout above multi-year resistance last week, sparked by the release of the CPI inflation data on Thursday. This move was one of the most eye-opening events of the week, drawing significant attention to small-cap stocks.
IWM's I... Read the Full Story |
|
Markets | |
International Gaming Technology PLC (NYSE: IGT) provides worldwide electronic gambling, gaming, and lottery products and services. It’s well known for providing most of the slot machines in Las Vegas in the pre-pandemic era. The company has expanded to include digital games through its Pla... Read the Full Story |
|
From Our Partners | | The Misery Index, a blunt inflation-and-unemployment gauge economists coined in 1970, just hit a three-year high.
Rising grocery bills, pricier fill-ups, and heavier mailboxes aren't just anecdotal, this index confirms the trend official data sometimes glosses over.
See what the Misery Index tracks and the one asset historically linked to its climb. | | See the index and the asset tied to its rise |
|
Finance | |
The insurance industry is being rattled by fintech disruptors like Lemonade Inc. (NYSE: LMND). Critics will say that underwriting policies are an art form and that human actuaries and adjusters can’t be replaced by artificial intelligence (AI). Insurance policies are best drawn up face-to-... Read the Full Story |
|
Consumer Staples | |
It’s no secret that most of the market’s attention has been centered around the technology sector, especially in stocks dealing with the advancement and global adoption of artificial intelligence, names like NVIDIA Co. (NASDAQ: NVDA) and even Taiwan Semiconductor Manufacturing (NYSE: T... Read the Full Story |
|
Consumer Staples | |
Fabless semiconductor developer Advanced Micro Devices Inc. (NASDAQ: AMD) stock had been largely unresponsive during the artificial intelligence (AI) boom as its shares peaked at $227.30 on March 8, 2024. On the other hand, rival NVIDIA Co. (NASDAQ: NVDA) has taken all the spotlight, hitting all... Read the Full Story |
|
Consumer Discretionary | |
The June CPI was much better than expected and has the broad market set up to rally over the next six to 12 months. The rally is driven by the expectation for FOMC interest rate cuts, which will reduce the cost of money and reinvigorate the bull market, assuming no recession unfolds. While most st... Read the Full Story |
|
Consumer Discretionary | |
As the dominant eCommerce giant, Alibaba Group Holding Ltd. (NYSE: BABA) is often considered the Amazon.com Inc. (NASDAQ: AMZN) of China. By sales, it's the third largest eCommerce giant in the world. With shares trading up just 3.6% year-to-date (YTD), it is also considerably underperforming th... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. | Should I Buy Alnylam Pharmaceuticals Stock? ALNY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Tuesday, August 25, 2026 at 6:48 PM.
Alnylam Pharmaceuticals Bull Case -
The stock has shown significant growth potential, with a recent price range indicating a high of around $495.55, suggesting strong market interest and investor confidence.
-
Alnylam Pharmaceuticals, Inc. reported impressive quarterly earnings, exceeding analysts' expectations, which reflects the company's robust financial health and operational efficiency.
-
The company has a high return on equity, indicating effective management and the ability to generate profits from shareholders' investments.
-
With a market capitalization of approximately $30.59 billion, Alnylam Pharmaceuticals, Inc. is positioned as a major player in the biopharmaceutical sector, attracting institutional investors.
-
The company has demonstrated a strong revenue growth of nearly 67% compared to the same quarter last year, showcasing its ability to expand and capture market share.
Alnylam Pharmaceuticals Bear Case -
The stock has a relatively high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
-
Despite recent revenue growth, the company did not meet its revenue estimates for the last quarter, which could raise concerns about future performance.
-
Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.75, suggesting that it relies on debt financing, which could pose risks if market conditions change.
-
Insider selling activity, such as the recent sale of shares by a director, may signal a lack of confidence in the stock's short-term performance.
-
The stock's beta of 0.30 indicates lower volatility compared to the market, which may limit potential gains during bullish market conditions.
| | View Today's Stock Pick |
|
